azacitidine has been researched along with Diathesis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cardamone, L; Paul, E; Rogers, B; Shaw, B; Shepherd, S; Shortt, J; Tey, A | 1 |
| Apostolopoulou, C; Bouchla, A; Loucari, C; Mpazani, E; Papageorgiou, SG; Pappa, V; Thomopoulos, TP | 1 |
| Edwards, JR; Hiken, JF; Song, J; Tian, F; VanderKraats, ND; Zhan, F; Zhang, H; Zhao, K | 1 |
| Al Ali, NH; Bart-Smith, E; Craig, BM; Epling-Burnette, PK; Komrokji, RS; Kordasti, S; Kulasekararaj, A; Lancet, JE; List, AF; Mufti, GJ; Padron, E; Pinilla-Ibarz, J; Zhang, L | 1 |
| Akria, L; Arad, A; Aviv, A; Braester, A; Dally, N; Filanovsky, K; Gafter-Gvili, A; Gatt, ME; Hellmann, I; Herishanu, Y; Herzog-Tzarfati, K; Leiba, R; Merkel, D; Mittelman, M; Nagler, A; Nemets, A; Ofran, Y; Ronson, A; Rouvio, O; Silbershatz, I; Tadmor, T; Vidal, L; Yeganeh, S | 1 |
| Kurosawa, T; Ookawara, T; Sugiyama, T; Suzuki, K; Taniguchi, N | 1 |
1 review(s) available for azacitidine and Diathesis
| Article | Year |
|---|---|
Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Disease Management; Disease Susceptibility; Humans; Mutation; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2021 |
5 other study(ies) available for azacitidine and Diathesis
| Article | Year |
|---|---|
Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antifungal Agents; Azacitidine; Disease Susceptibility; Female; Humans; Incidence; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neutropenia; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2021 |
DNMT gene expression and methylome in Marek's disease resistant and susceptible chickens prior to and following infection by MDV.
Topics: Animals; Azacitidine; Cell Line; Chick Embryo; Chickens; Disease Resistance; Disease Susceptibility; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Herpesvirus 2, Gallid; Marek Disease | 2013 |
Autoimmune diseases and myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Comorbidity; Disease Progression; Disease Susceptibility; Female; Follow-Up Studies; Hashimoto Disease; Humans; Immunocompromised Host; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prevalence; Proportional Hazards Models; Retrospective Studies; Thalidomide; Thyroiditis, Autoimmune; Young Adult | 2016 |
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Disease Susceptibility; Female; Humans; Incidence; Infections; Israel; Leukemia, Myeloid, Acute; Male; Methylation; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Retrospective Studies; Risk Factors; Severity of Illness Index; Thrombocytopenia | 2013 |
High sensitivity to 5-azacytidine in LEC rats, a strain with a metabolic predisposition to hepatitis and hepatoma: possible involvement of DNA methylation in the expression of cytochrome P-450 and gamma-glutamyl transpeptidase.
Topics: 5-Methylcytosine; Animals; Azacitidine; Cytochrome P-450 Enzyme System; Cytosine; Disease Susceptibility; DNA; DNA (Cytosine-5-)-Methyltransferases; gamma-Glutamyltransferase; Gene Expression Regulation, Enzymologic; Hepatitis, Animal; Liver; Liver Neoplasms, Experimental; Methylation; Rats; Rats, Mutant Strains | 1991 |